TY - JOUR
T1 - Baseline predictors of vitreomacular adhesion/traction resolution following an intravitreal injection of ocriplasmin
AU - Jackson, Timothy L.
AU - Regillo, Carl D.
AU - Girach, Aniz
AU - Dugel, Pravin U.
PY - 2016/8
Y1 - 2016/8
N2 - BACKGROUND AND OBJECTIVE: To determine factors predicting response to ocriplasmin (Jetrea; ThromboGenics, Iselin, NJ) response in patients with symptomatic vitreomacular adhesion (VMA). PATIENTS AND METHODS: Combined analysis of two multicenter, prospective, randomized, double-masked trials of intravitreal ocriplasmin 125 μg injection versus placebo. Patients had vitreomacular traction with or without a full-thickness macular hole (FTMH). Multivariate logistic regression was used to determine factors influencing treatment response (complete VMA release [day 28] and nonsurgical FTMH closure [month 6]). RESULTS: Younger age, presence of FTMH (odds ratio [OR] = 2.1; 95% confidence interval [CI], 1.1- 3.7), VMA diameter of 1,500 μm or less (OR = 4.9; 95% CI, 2.0-12.4), phakic lens status (OR = 2.8; 95% CI, 1.5-5.2), and absence of epiretinal membrane (OR = 4.1; 95% CI, 2.2-7.9) predicted VMA resolution. FTMHs with apical diameter of 250 μm or less were more likely to close than larger holes (58.3% vs. 24.6%; P = .013). Both FTMH size groups had significantly greater chance of VMA resolution and FTMH closure versus controls. CONCLUSION: Ocriplasmin is most effective in younger patients with focal VMA and without an epiretinal membrane.
AB - BACKGROUND AND OBJECTIVE: To determine factors predicting response to ocriplasmin (Jetrea; ThromboGenics, Iselin, NJ) response in patients with symptomatic vitreomacular adhesion (VMA). PATIENTS AND METHODS: Combined analysis of two multicenter, prospective, randomized, double-masked trials of intravitreal ocriplasmin 125 μg injection versus placebo. Patients had vitreomacular traction with or without a full-thickness macular hole (FTMH). Multivariate logistic regression was used to determine factors influencing treatment response (complete VMA release [day 28] and nonsurgical FTMH closure [month 6]). RESULTS: Younger age, presence of FTMH (odds ratio [OR] = 2.1; 95% confidence interval [CI], 1.1- 3.7), VMA diameter of 1,500 μm or less (OR = 4.9; 95% CI, 2.0-12.4), phakic lens status (OR = 2.8; 95% CI, 1.5-5.2), and absence of epiretinal membrane (OR = 4.1; 95% CI, 2.2-7.9) predicted VMA resolution. FTMHs with apical diameter of 250 μm or less were more likely to close than larger holes (58.3% vs. 24.6%; P = .013). Both FTMH size groups had significantly greater chance of VMA resolution and FTMH closure versus controls. CONCLUSION: Ocriplasmin is most effective in younger patients with focal VMA and without an epiretinal membrane.
UR - http://www.scopus.com/inward/record.url?scp=84986893118&partnerID=8YFLogxK
U2 - 10.3928/23258160-20160808-04
DO - 10.3928/23258160-20160808-04
M3 - Article
C2 - 27548448
AN - SCOPUS:84986893118
SN - 2325-8160
VL - 47
SP - 716
EP - 723
JO - Ophthalmic Surgery Lasers and Imaging Retina
JF - Ophthalmic Surgery Lasers and Imaging Retina
IS - 8
ER -